Stockscreener 앱 받기
17.75
4.55%
-0.845
시장 영업 전:
17.75
0.005
+0.03%
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
UroGen Pharma's Q2 2025 Earnings: A Catalyst for Valuation Re-Rating in Uro-Oncology? - AInvest
UroGen Pharma Q2 2025 Earnings Call Transcript - AInvest
UroGen Pharma Ltd. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:URGN) - Seeking Alpha
Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target - AInvest
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
Guggenheim raises UroGen Pharma stock price target to $32 on Zusduri launch - Investing.com Australia
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI - TipRanks
UroGen Pharma Q2 Earnings Call: FDA Approval, Revenue Growth, and Expanded Sales Force - AInvest
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA A - GuruFocus
UroGen Pharma Outpaces Forecasts With Revenue And FDA Nod - Finimize
Urogen Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Health Care Stocks Slipped As Big Players Disappointed - Finimize
UroGen Pharma (URGN) Receives Consistent "Buy" Rating from D. Boral Capital | URGN Stock News - GuruFocus
Sector Update: Health Care - MarketScreener
UroGen Pharma Tops Revenue Forecasts With FDA Approval In Tow - Finimize
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth - Investing.com
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth By Investing.com - Investing.com South Africa
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com
UroGen Pharma earnings missed by $0.22, revenue topped estimates - Investing.com Australia
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDUR - GuruFocus
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
UroGen Pharma Ltd. SEC 10-Q Report - TradingView
Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q2 Revenue $24.2M, vs. FactSet Est of $23.1M - MarketScreener
UroGen Pharma Expands Commercial Portfolio with Launch of - GlobeNewswire
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - Yahoo Finance
UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis - GuruFocus
UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revisions - GuruFocus
UroGen’s Zusduri benefit maintained in NMIBC Phase III study - Yahoo Finance
URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target - GuruFocus
D. Boral Capital Maintains Buy Rating for UroGen Pharma with $25 Price Target - AInvest
UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bla - GuruFocus
URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target | URGN Stock News - GuruFocus
UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bladder Cancer Treatment - GuruFocus
UroGen Pharma: D. Boral Capital maintains Buy, PT raised to $25 from $25. - AInvest
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewswire
Breakthrough: New Bladder Cancer Drug Shows 72% Success Rate in Phase 3 Trial Results - Stock Titan
What institutional investors are buying UroGen Pharma Ltd. stockAchieve superior returns through strategic trading - Jammu Links News
How strong is UroGen Pharma Ltd. company’s balance sheetPhenomenal capital gains - Jammu Links News
What is UroGen Pharma Ltd. company’s growth strategyAchieve superior capital gains with smart trades - Jammu Links News
Does UroGen Pharma Ltd. stock perform well during market downturnsInvest confidently with professional advice - Jammu Links News
What are the technical indicators suggesting about UroGen Pharma Ltd.Rapid portfolio appreciation - Jammu Links News
Is UroGen Pharma Ltd. a growth stock or a value stockAchieve consistent profits with expert advice - Jammu Links News
Should I hold or sell UroGen Pharma Ltd. stock in 2025Unlock exclusive stock market forecasts - Jammu Links News
What markets is FTAIN expanding into Is UroGen Pharma Ltd. stock a good long term investment optionDouble or triple returns - Jammu Links News
What catalysts could drive UroGen Pharma Ltd. stock higher in 2025Build wealth steadily with proven investment techniques - Jammu Links News
How does UroGen Pharma Ltd. compare to its industry peersRetirement Planning Alerts That Work - Jammu Links News
Is UroGen Pharma Ltd. stock overvalued or undervaluedBreakout Stocks Strategy With Low Risk - jammulinksnews.com
0.24%
3.39%
자본화:
|
볼륨(24시간):